IM HealthScience (IMH) was founded in 2012 by a group of senior pharmaceutical executives as a science driven and patient centric company whose mission is to research, develop and make available state of the art medical foods for gastrointestinal conditions such as Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD).

IMH is a family company rooted in the all too forgotten adage that the patient comes first and doing the right thing will always win out in the long term.

As a small, private organization, IMH is committed to putting patients before profits. IMH is also committed to bringing cutting edge life science and world class clinical research to the medical foods industry.

IMH has launched IBgard® nationally in 2015 for patients with IBS. IBgard has been very well received by patients who have given their feedback to their physicians. In the meantime, the medical consensus around IBgard and its utility in IBS has been further strengthened by the emergence of three important studies, IBSREST™, IBSRRET™ and IBSACT™ presented at DDW, AGA and ACG. This medical consensus has been further confirmed by the formal approval of IBgard by Health Canada in 2015.

www.imhealthscience.com